Speech treatment in Parkinson's disease: Randomized controlled trial (RCT).

ABSTRACT:

Background

As many as 89% of people with Parkinson's disease (PD) develop speech disorders.

Objectives

This randomized controlled trial evaluated two speech treatments for PD matched in intensive dosage and high-effort mode of delivery, differing in subsystem target: voice (respiratory-laryngeal) versus articulation (orofacial-articulatory).

Methods

PD participants were randomized to 1-month LSVT LOUD (voice), LSVT ARTIC (articulation), or UNTXPD (untreated) groups. Speech clinicians specializing in PD delivered treatment. Primary outcome was sound pressure level (SPL) in reading and spontaneous speech, and secondary outcome was participant-reported Modified Communication Effectiveness Index (CETI-M), evaluated at baseline, 1, and 7 months. Healthy controls were match

SUBMITTER: Ramig L 

PROVIDER: S-EPMC6261685 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature